On-Demand Presentations and Slides

Multidisciplinary Treatment Strategies in CRC to Optimize Patient Outcomes

Release date 08-06-2022

Expiration date 07-06-2023

The management of colorectal cancer (CRC) is challenging and selecting the most appropriate treatment strategy for an individual patient often requires a multidisciplinary team (MDT) approach. Treatment approaches are rapidly evolving for both patients with localized disease and those with metastatic CRC with distinct tumor subtypes. At the virtual Preceptorship in CRC, organized in collaboration with Zhongshan Hospital in Shanghai, multidisciplinary experts in the field discussed the latest advances in the management of CRC. View presentations, slides, and clinical cases from this meeting, and gain valuable insights for your practice.

The presentations and slides are based on the Preceptorship that took place on 14 and 15 April 2022.

Faculty

Jianmin Xu, MD, PhD

Jianmin Xu, MD, PhD | Course Director

Zhongshan Hospital

Fudan University

Shanghai, China

Jianmin Xu is Chief Physician and Doctoral Supervisor at the Zhongshan Hospital, Fudan University, Shanghai. He is also Director of the Colorectal Cancer Center and Colorectal Surgery Department at Zhongshan Hospital, and Director of the Shanghai Engineering Research Center of Colorectal Cancer Minimally Invasive Technology. He studied at the Massachusetts General Hospital, US in 2001 and at Ambroise Paré Hospital (Paris Medical School), France in 2004. Professor Xu’s scientific interests are focused on gastrointestinal cancer, especially basic research and clinical treatment of colorectal cancer and liver metastasis. He has established a standardized treatment of early diagnosis and therapy, developed minimally invasive surgery techniques, and discovered new molecular targets and explored their mechanisms. He has also trained more than 20 postgraduate students, edited 5 books, published more than 70 SCI journal papers as first or corresponding author, and served as an editor or reviewer for more than 10 academic journals, including deputy editor of OncoTargets and Therapy.  Professor Xu drafted the Chinese Guidelines for Diagnosis and Comprehensive Treatment of Hepatic Metastasis of Colorectal Cancer, Expert Consensus of Robotic Surgery in Colorectal Cancer (2015 edition), and Robotic Surgery Guideline of National Health and Family Planning Commission (NHFPC).

Professor Xu is a Vice Chairman of the Colorectal Cancer Professional Committee at the Chinese Medical Doctor Association (CMDA); Chairman of the Robotic Surgery Group of the Colorectal Cancer Professional Committee at CMDA; Chairman of the Metastasis Research Committee, Anorectal Branch at CMDA; Deputy General Secretary & Executive Member of the Colorectal Surgeon Committee at CMDA; Vice Chairman of the Colorectal Cancer Expert Committee at the Chinese Society of Clinical Oncology (CSCO);Member of Colorectal Surgery Group of Surgery Committee at Chinese Medical Association (CMA); Vice Chairman of the Colorectal Cancer Expert Committee and Leader of the Liver Metastasis Group at the Chinese Anti-Cancer Association (CACA); Executive Member of the Metastasis Committee, Vice Chairman of the Big Data and Real-World Research Committee at CACA; Vice Chairman of the Therapy Committee of Colorectal Cancer and Metastasis at China International Exchange and Promotive Association for Medical and Health Care (CPAM); Chairman of the Colorectal Cancer Professional Committee at the Union of Oncology Management, Shanghai China (UCOM), and Vice Chairman of the Robotic and Laparoscopic Surgery Professional Committee, Chinese Research Hospital Association (CRHA).

Yunshi Zhong, MD, PhD

Yunshi Zhong, MD, PhD

Zhongshan Hospital

Fudan University

Shanghai, China

Yunshi Zhong is a Chief Physician, Associate Professor, and Deputy Director of the Endoscopy Center, Zhongshan Hospital, Fudan University. He is also Vice Chairman of TEM Group, Professional Committee of Colorectal Cancer, Chinese Medical Doctor Association (CMDA); Vice Chairman of the Early Diagnosis and Treatment Group, Professional Committee of Colorectal Cancer, Chinese Medical Doctor Association (CMDA); and Youth Committee Member and Vice Chairman of TEM Group, Professional Committee of Colorectal Cancer, Chinese Anti-Cancer Association. Furthermore, Professor Zhong is Director of the Board of Chinese Society of Clinical Oncology (CSCO); Executive President and Secretary-General of the Minimally Invasive Alliance of Digestive Endoscopy, World Association of Endoscopists; Secretary-General of the Professional Committee of Gastrointestinal Endoscopy, Shanghai Anti-cancer Association; and Vice Chairman of the Youth Group, Shanghai Society of Gastrointestinal Endoscopy.

Zhen Zhang, MD, PhD

Zhen Zhang, MD, PhD

Shanghai Cancer Center

Fudan University

Shanghai, China

Zhen Zhang is the Director of Radiotherapy Center of Fudan University Cancer Center, Chief Physician, and a Professor and Doctoral Supervisor. She graduated from the Department of Medicine, Shanghai Medical University in 1988, studied in the Department of Radiotherapy of MD Anderson Cancer Center USA from 2000 to 2001, and received a PhD in Oncology from Fudan University Shanghai Cancer Center in 2007. Dr. Zhang is Vice Chairman of the Radiation Oncology Committee of Chinese Medical Association (CMA), Vice Chairman of the Radiotherapy Branch of Chinese Medical Doctor Association (CMDA), Vice Chairman of the Radiation Oncology Committee of CSCO, Vice Chairman of the Radiation Protection Committee of Chinese Anti-Cancer Association (CACA), Chairman of the Radiotherapy Committee of Shanghai Anti-cancer Association, Chairman of the Radiotherapy Committee of Shanghai Medical Association, Shanghai Leading Talent, NCI Rectal Cancer Working Group Member, and NRG Non-CRC Committee Member. Her main focus is on radiotherapy and the multidisciplinary treatment of gastrointestinal cancer, malignant lymphoma, breast cancer and other abdominal and pelvic cancers; she also directs scientific research into the comprehensive treatment of gastrointestinal cancer, innovative radiotherapy techniques, application of image-guided radiotherapy, and individualized treatment in oncology.

Tianshu Liu, MD, PhD

Tianshu Liu, MD, PhD

Department of Medical Oncology

Zhongshan Hospital, Fudan University

Shanghai, China

Tianshu Liu is Chief Physician, Doctoral Supervisor, and Director of Oncology at Zhongshan Hospital, Fudan University, Shanghai. She is also Director of Education and Research Department of Oncology, Director of Early Cancer Research Ward, Member of Ethics Committee; and Secretary General of Cancer Prevention and Control Center, Zhongshan Hospital, Fudan University.

Professor Liu is a dedicated clinical researcher, primarily focused on biomarkers and new treatment strategies for advanced colorectal and gastric cancer. Since 2012, she has served as the PI in Zhongshan Hospital for more than 70 clinical trials, including many international Phase I–III trials; the findings of these trials have been published in prestigious journals including the Journal of Clinical Oncology, JAMA, and Lancet Oncology. She has also been the corresponding author on more than 50 scientific papers over the last 5 years. Professor Liu has received several awards including the Shanghai Medical Scientific Award in 2020 for her work “The Establishment and Promotion of the Standardized System of Whole-process Management of Colorectal Cancer”.

Professor Liu is Chairman of Clinical Epidemiology and Evidence-based Medicine Specialty, Shanghai Medical Association; Director of the Shanghai Cancer Chemotherapy Quality Control Center; Vice Chairman of the Chemotherapy Drug Safety Management Committee and Translational Medicine Committee of the Chinese Society of Clinical Oncology (CSCO); Standing Committee Member of Clinical Research Committee/Gastric Cancer Committee of CSCO; Standing Committee Member of the Big Data of Oncology and Real-world Research Committee of Chinese Anti-Cancer Association; Member of the Shanghai Clinical Research Ethics Committee; Standing Committee Member of the Oncology Targeted Therapy Technology Committee of Chinese Society of Biomedical Engineering; and Standing Committee Member of the Tumor Rehabilitation Branch of Chinese Geriatrics Association. She has also been awarded honorary titles including “The Fourth National Famous Doctor – Excellent Style”, the Third “Renxin Doctor – Shanghai Distinguished Specialist Doctor Award”, and the Third “Shanghai Most Beautiful Doctor”.

Li Ren, MD

Li Ren, MD

Zhongshan Hospital

Fudan University

Shanghai, China

Li Ren is an Associate Chief Physician, Deputy Director of the Department of Colorectal Surgery in Zhongshan Hospital, Fudan University, Director of the Colorectal Cancer Center Office, and Director of the Shanghai Colorectal Tumor Minimally Invasive Engineering Technology Research Center Office. He is a Member of the Promotion and Application of Medical Oncology Standardized Practice Committee of Oncology Branch of Chinese Medical Association and Leader of the Surgery Group. Furthermore, Professor Ren is a Member of the Colorectal Cancer Expert Committee of the Chinese Society of Clinical Oncology (CSCO); Member of the Surgery Group, Liver Metastasis Group and Sub-micro Group of Colorectal Committee of Chinese Medical Doctor Association (CMDA); Youth Member of the Colorectal Surgeon Committee of Chinese College of Surgeons of CMDA; Member of the Inflammatory Enterologist Branch of CMDA; and Member of the Genetics Group of Colorectal Cancer Committee of the Chinese Anti-Cancer Association (CACA). In addition, he is the Executive Secretary and Member of the Colorectal Cancer Liver Metastasis Therapy Committee of Chinese International Exchange and Promotive Association; Member of the Chinese Academy of Surgical Colorectal Surgery; Deputy Leader of the Liver Metastasis Group of Colorectal Cancer Committee of Shanghai Anti-cancer Association; and Member of the Target Molecule Committee of Shanghai Medical Association.

Xiaoying Wang, MD, PhD

Xiaoying Wang, MD, PhD

Zhongshan Hospital

Fudan University

Shanghai, China

Xiaoying Wang is Chief Physician, Professor and Doctor of Surgery at Zhongshan Hospital, Fudan University, Shanghai. He is also the Director of Minimally Invasive Sub-Specialty of Liver Surgery at Zhongshan Hospital. He completed a fellowship in minimally invasive surgery and robotic surgery at the University of Illinois, Chicago, US from 2012 to 2013. Professor Wang‘s clinical interests include minimally invasive surgery for liver tumors and liver transplantation, and his surgical experience includes laparoscopic and robotic hepatectomy, laparoscopic ablation of liver tumors, complex hepatobiliary surgery, and living donor liver transplantation. Professor Wang’s research focuses on new techniques of minimally invasive liver surgery – he developed the technique of portal vein puncture with ICG fluorescence staining for the robotic and laparoscopic anatomic segmentectomy, and also the fluorescence staining method for sentinel lymph node of intrahepatic cholangiocarcinoma. Fifteen SCI papers are published with Professor Wang as first and corresponding author. He is a member of several societies and associations, including an Executive Committee Member of the Clinical Robotic Surgery Society (CRSA); a Founding Member of the International Society for Laparoscopic Hepatology (ILLS); a Member of the International Association of Surgeons, Gastroenterologists and Oncologists (IASGO); a Member of Asia-Pacific Expert Committee on Promotion and Development of Laparoscopic Hepatectomy Expert Committee Member of Asia-Pacific Committee on Promotion and Development of Laparoscopic Hepatectomy of International Association of Liver, Biliary and Pancreas; a Member of Chinese Expert Committee on Promotion and Development of Laparoscopic Hepatectomy; a Member of Robotic Doctor Branch of Chinese Medical Doctor Association (CMDA); a Member of the Robotic Surgery Group, Surgeon Branch of Chinese Medical Doctor Association (CMDA), and a Member of the Liver Surgery Group, Shanghai Medical Association. Professor Wang is also an Editorial Board Member of the Chinese Journal of Surgery.

Ying Yuan, MD, PhD

Ying Yuan, MD, PhD

Department of Medical Oncology

The Second Affiliated Hospital
Zhejiang University School of Medicine

Hangzhou, China

Yuan Ying has been a Chief Medical Oncologist at The Second Affiliated Hospital, Zhejiang University School of Medicine, Zhejiang, China, since 1998. During her career, she has completed 2 years’ postdoctoral training at Lubeck Medical University in Germany and also spent a short period of time at Dana-Farber Cancer Center and Massachusetts General Hospital in Boston, US. Professor Yuan has been engaged in the clinical diagnosis and treatment of malignant tumors for more than 20 years. Her research focus is the clinical and genetic studies of hereditary colorectal cancer, as well as personalized and comprehensive treatment of gastrointestinal and various other solid tumors. Currently, Professor Yuan is the Executive Deputy Editor and Managing Director of Journal of Practical Oncology. She is also a Standing Committee Member of Colorectal Cancer Branch, Chinese Anti-Cancer Association, a Standing Committee Member and Leader of the Genetic Group of the Committee of Colorectal Cancer at the Chinese Anti-Cancer Association (CACA), a Trustee of the Chinese Society of Clinical Oncology (CSCO), and a Vice Chairman of the CSCO Committee of Colorectal Cancer.

Young Suk Park, MD, PhD

Young Suk Park, MD, PhD

Samsung Medical Center

Sungkyunkwan University School of Medicine

Seoul, Korea

Young Suk Park is a Professor at the Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center – Sungkyunkwan University Medical School, Seoul, Korea. Dr Park received his medical degree from Seoul National University College of Medicine, Seoul, Korea. He has worked as the Director of the Clinical Trial Center in Samsung Medical Center and also served as the Chairman of the Colorectal Cancer Subcommittee of the Korean Cancer Study Group (KCSG) and the Chairman of the Korean NET Forum. Dr Park has been involved in many national projects for the development of clinical trial support and training programs. His primary clinical interest is the treatment of gastrointestinal cancers, with an emphasis on conducting clinical trials as an active investigator; he has been the principal investigator of several clinical trials since 2002. In addition, Dr Park has written several book chapters and authored about 200 published articles in international journals.

Kei Muro, MD, PhD

Kei Muro, MD, PhD

Aichi Cancer Center Hospital

Nagoya, Japan

Kei Muro is Chief and Director of the Department of Clinical Oncology and Outpatient Treatment Center at Aichi Cancer Center Hospital in Nagoya, Japan. In addition, he was promoted to Deputy Director of the Aichi Cancer Center Hospital in 2018. He is an Adjunct Professor at Nagoya University Graduate School of Medicine and Tokyo University Graduate School of Medical Science, and is an adjuvant and Clinical Professor at Nagoya City University Graduate School of Medical Science. Dr. Muro is an executive board member of the Japanese Society of Medical Oncology and the Japanese Gastric Cancer Association. In addition, he is a council member of the Japan Esophageal Society, Japan Society of Coloproctology, and Japanese Cancer Association. He is a member of the American Society of Clinical Oncology, and was a faculty member for gastrointestinal tumors of the European Society for Medical Oncology from 2017 to 2021. Dr. Muro collaborates with the World Health Organization on the Japanese Gastric Cancer Committee. In terms of clinical trial activity, he is the Chair of the Gastrointestinal Cancer Group of the West Japan Oncology Group. He is an author on more than 360 peer-reviewed journal publications and is a reviewer for the Japanese Journal of Clinical Oncology and Esophagus. In 2012, Dr. Muro was awarded the Nagoya International Cancer Treatment Symposium BMS Award and, in 2013, the Excellent Presentation Award of the Japan Society of Clinical Oncology.

Jaw-Yuan Wang, MD, PhD

Jaw-Yuan Wang, MD, PhD

Kaohsiung Medical University Chung-Ho

Memorial Hospital

Kaohsiung, Taiwan

Jaw-Yuan Wang is a Professor of Surgery at Kaohsiung Medical University, Kaohsiung, Taiwan, where he also serves as Director of the Department of Medical Research at Kaohsiung Medical University Hospital. After receiving his medical and doctoral degrees from Kaohsiung Medical University, Professor Wang trained at the State University of New York in the US. He currently serves as the Superintendent of Pingtung Hospital, Taiwan, the leader of the Colorectal Cancer Multidisciplinary Team, the Program Director of Robotic Surgery, and the Chairman of the Nutrition Support Council at Kaohsiung Medical University Hospital.

Professor Wang is an active member in numerous professional organizations and serves as Past-President of the Society of Colon and Rectal Surgeons in Taiwan, Executive Director of the Board of the Taiwan Surgical Society, Director of the Board of the Taiwan Society of Coloproctology, Executive Director of the Board of the Taiwan Society of Parenteral and Enteral Nutrition, and Executive Director of the Board of the Taiwan Genomic Medicine and Biomarker Society. He has been the recipient of numerous awards and has published more than 300 SCI peer-reviewed journal articles and 6 book chapters. Professor Wang also serves as an editor for several international journals, including the World Journal of Gastroenterology, Asian Journal of Surgery, Kaohsiung Journal of Medical Science, Frontiers in Oncology, Cells, and Oncology Letters. In 2020, he was invited to the Global Reach Committee of European Society of Coloproctology (ESCP).

Feng Wang, MD, PhD

Feng Wang, MD, PhD

Sun Yat-sen University Cancer Center

Guangzhou, China

Feng Wang is Vice Director of the Department of Medical Oncology at Sun Yat-sen University Cancer Center, Guangzhou, China. She received her MD from Sun Yat-sen University and a PhD from MD Anderson Cancer Center, US. Her research focuses on clinical and biomarker-guided treatment optimization and metabolic regulatory mechanisms in gastrointestinal (GI) cancers, and she has extensive experience and expertise in the field of GI medical oncology and translation research in GI cancers. She has authored over 90 peer-reviewed articles, including some as first author or corresponding author in renowned journals, such as JAMA Oncol, Cell Res, and Ann Oncol,and she has also been invited to present results at AACR, CSCO, and other international conferences. Professor Wang has received several awards, including First Prize of the Chinese Medical Science & Technology Award and First Prize for Science & Technology Development from the Ministry of Education. She is a Chairing Committee member of CSCO and Vice Director of the Youth Committee of the Professional Committee of Tumor-Targeted Therapy for the Chinese Anti-Cancer Association. She is a member of ASCO and AACR.

  • Managing colorectal cancer in Zhongshan Hospital: Facts and figures
    Jianmin Xu, MD, PhD

Early-stage CRC

 

  • Advances in the management of early colorectal cancer
    Yunshi Zhong, MD, PhD

  • State-of-the-art management of localized rectal cancer
    Zhen Zhang, MD, PhD       

  • Keynote presentation: Expanding biomarkers for personalized treatment of mCRC
    Tianshu Liu, MD, PhD

CRC with oligometastatic disease

 

  • Diagnosis and multidisciplinary treatment of colorectal liver metastases: Current recommendations
    Li Ren, MD

  • A closer look at strategies to increase cure in patients with unresectable CRLM
    Xiaoying Wang, MD, PhD

  • Principles of multidisciplinary therapy of lung metastases in CRC
    Ying Yuan, MD, PhD

Metastatic CRC

 

  • Navigating treatment for RAS wild-type mCRC: First-line and beyond progression
    Young Suk Park, MD, PhD

  • Update on the use of immunotherapy in advanced CRC
    Kei Muro, MD, PhD

  • Optimal treatment of BRAF-mutant CRC
    Jaw-Yuan Wang, MD, PhD

  • Evolving therapies for HER2-amplified and KRAS-mutant mCRC
    Feng Wang, MD, PhD

This program is designed for medical oncologists, surgeons, and radiation oncologists involved in the management of colorectal cancer.

Upon completion of this educational activity, participants should be able to:

 

  • Apply multimodality treatment strategies that may lead to optimal treatment outcomes and/or better quality of life in early and metastatic CRC
  • Evaluate biomarkers to guide precision medicine in mCRC and discuss role of next generation sequencing and clinical applications of liquid biopsy
  • Select optimal frontline therapy for mCRC and treatment strategies across the disease continuum for RAS wild-type CRC, including anti-EGFR rechallenge
  • Determine the optimal treatment approach for BRAF-mutant mCRC, and assess emerging options for HER2-amplified and KRAS-mutant mCRC
  • Explain role of immunotherapy in mCRC

This educational activity is provided by ACE Oncology.

This educational activity is supported by an independent grant from the Healthcare business of Merck KGaA, Darmstadt, Germany.

This activity provides content that is evidence-based, balanced, and free of commercial bias, with a primary objective to improve the competence and performance of learners in order to improve patient care.

The faculty reported the following financial relationships or relationships to products or devices they or their spouses/life partners have with commercial interest related to the content of this activity:

 

Jianmin Xu has no financial relationships to disclose. Any unlabeled/unapproved uses of drugs or products referenced in his presentation will be specified.

 

Yunshi Zhong has no financial relationships to disclose. Any unlabeled/unapproved uses of drugs or products referenced in his presentation will be specified.

 

Zhen Zhang has received grants for clinical research from TopAlliance. Any unlabeled/unapproved uses of drugs or products referenced in her presentation will be specified.

 

Tianshu Liu has no financial relationships to disclose. Any unlabeled/unapproved uses of drugs or products referenced in her presentation will be specified.

 

Li Ren has no financial relationships to disclose. Any unlabeled/unapproved uses of drugs or products referenced in his presentation will be specified.

 

Xiaoying Wang has no financial relationships to disclose. Any unlabeled/unapproved uses of drugs or products referenced in his presentation will be specified.

 

Ying Yuan has no financial relationships to disclose. Any unlabeled/unapproved uses of drugs or products referenced in her presentation will be specified.

 

Young Suk Park has no financial relationships to disclose. Any unlabeled/unapproved uses of drugs or products referenced in his presentation will be specified.

 

Kei Muro has served as an advisor or consultant for Amgen, AstraZeneca, Ono, and Chugai. Dr Muro has served as a speaker or a member of a speakers bureau for Eli Lilly, Chugai, Takeda, Ono, Taiho, Sanofi, Bristol-Myers Squibb, and Bayer. He has received grants for clinical research from Astellas, Amgen, Sanofi, Daiichi Sankyo, Parexel International, Taiho, MSD, Merck Biopharma, Pfizer, Eisai, Solasia Pharma, Eisai, and Ono. Any unlabeled/unapproved uses of drugs or products referenced in his presentation will be specified.

 

Jaw-Yuan Wang has no financial relationships to disclose. Any unlabeled/unapproved uses of drugs or products referenced in his presentation will be specified.

 

Feng Wang has no financial relationships to disclose. Any unlabeled/unapproved uses of drugs or products referenced in her presentation will be specified.

 

The employees of ACE Oncology have disclosed no relevant financial relationships.

 

ACE Oncology requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COIs are thoroughly vetted and resolved according to ACE Oncology’s policy. ACE Oncology is committed to providing its learners with high-quality activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial entity.

 

 

Start Activity